Revance Therapeutics (RVNC) Stock Price, News & Analysis

Company Overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Key Stats

• Today's Range: $3.65 to $3.65
• 50-Day Range: $3.65 to $3.65
• 52-Week Range: $2.76 to $6.65
• Volume: N/A
• Average Volume: 3.78 million shs
• Market Capitalization: $381.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.23
• Consensus Rating: Hold

Revance Therapeutics Stock Analysis - MarketRank™

Revance Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 775th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Revance Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Revance Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Revance Therapeutics are expected to grow in the coming year, from ($1.57) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for RVNC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Revance Therapeutics does not currently pay a dividend.

Dividend Growth

Revance Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.88

Short Interest

There is no current short interest data available for RVNC.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Revance Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.10% of the stock of Revance Therapeutics is held by insiders.

Percentage Held by Institutions

97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RVNC Stock Analysis - Frequently Asked Questions

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.12. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year.
Read the conference call transcript.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revance Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 8/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RVNC
• CIK: 1479290
• Web: www.revance.com
• Phone: (615) 724-7755
• Fax: 510-742-3401
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Revance Therapeutics: $4.23
• High Price Target: $6.60
• Low Price Target: $3.00
• Potential Upside/Downside: +16.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$323.99 million
• Net Margins: -74.67%
• Pretax Margin: -122.07%
• Return on Equity: N/A
• Return on Assets: -37.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.12
• Quick Ratio: 3.05

Sales & Book Value

• Annual Sales: $234.04 million
• Price / Sales: 1.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.73) per share
• Price / Book: -2.11

Miscellaneous

• Outstanding Shares: 104,390,000
• Free Float: 99,066,000
• Market Cap: $381.02 million
• Optionable: Optionable
• Beta: 0.90